Ciro Improta

Visiting research fellow @BostonChildrens |Hematology fellow @HumanitasMilano
|MD graduate @MyUniSR |

[Nature Biotechnology @NatureBiotech]

Directed evolution of small RNA-stabilizing motifs that improve prime-editing efficiency https://t.co/h54EB3gf7T

[Benlazar S M A @smbenlazar]

Brentuximab vedotin plus nivolumab as bridging therapy to CAR T-cells in relapsed/refractory primary mediastinal B-cell lymphoma | Haematologica https://t.co/1U6KGvo5yt #lymsm

[David R. Liu @davidrliu]

Today in @Nature we report a new prime editing strategy that can rescue a common cause of many genetic diseases in a disease-agnostic manner. This approach converts a redundant endogenous tRNA into an optimized suppressor tRNA, enabling a single prime edit to rescue premature stop codons across different diseases.
(1/15)
https://t.co/zs0qu5bhXx

[Weixin Tang @WeixinT]

This week we publish in @NatureBiotech "High-precision cytosine base editors by evolving nucleic-acid-recognition hotspots in deaminase". In this work, we show that both nucleotide and context specificity of deaminases can be reprogrammed by hotspot-focused directed evolution 1/n

[Ilaria Iacobucci @IlariaIacobucc1]

📣 Cell developmental state matters in B-ALL. Our study out today in ⁦@NatureCancer⁩: Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical features | Nature Cancer https://t.co/wsL2HsaI0G

[Lymphoma Hub @lymphomahub]

🚨 NEWS 🚨

The @EU_Commission approves brentuximab vedotin in combination with ECADD (BrECADD) for the treatment of newly diagnosed patients with Stage IIb/III/IV Hodgkin lymphoma.

Learn more: https://t.co/VCKftCSMEc

#lymphoma #lymsm #MedNews

[Marios Georgakis @MariosGeorgakis]

Most genetic variants are assumed to influence disease risk by effects on gene expression. While most variants can affect the expression of multiple genes, existing methods map a single gene at a time.

Clustering the expression of neighboring genes can improve eQTL discovery👇

[Ximena Jordan Bruno @XimeJordan]

TP53 mutations are associated with CD19− relapse and inferior outcomes after blinatumomab in adults with ALL | Blood Advances | American Society of Hematology https://t.co/GwaYSwRWwy

[Eric Topol @EricTopol]

A new epigenetic clock —DNAmIC—outperforms others for identifying risk of all-cause mortality, and linked with lifestyle and immune system factors @NatureAging
https://t.co/AOeXX0IAeV

[Raul Cordoba, MD, PhD #EHA2026 @DrRaulCordoba]

#Hematology Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell #lymphoma #PMBCL # lymsm https://t.co/J6C4puMHlN

[Waggoner Lab @LabWaggoner]

Review @AnnualReviews
Molecular Mechanisms Governing CD8 T Cell Differentiation and Checkpoint Inhibitor Response in Cancer
https://t.co/RqhpJXQqjY
1, and 1

[Robert Z. Orlowski @Myeloma_Doc]

#Myeloma Paper of the Day: Myeloma with 1q gain/amplification exhibits reduced CD38 expression via interleukin-6 receptor over-expression, and inhibition of the IL-6/JAK/STAT pathway by treatment w/ ruxolitinib or tocilizumab restores CD38 levels: https://t.co/XSGlxe7fpH. #mmsm

[Blood Advances @BloodAdvances]

11% patients diagnosed with ITP carried diagnostic grade variants for inherited thrombocytopenia or primary immunodeficiency. https://t.co/SFEeImp7Kv #plateletsandthrombopoiesis

[May Daher @may_daher]

Very excited to share our latest research article published with @SpringerNature in @NatureComms. We show that in early #MDS, NK cells share mutations with the malignant clones, becoming dysfunctional and failing to eliminate aberrant stem cells. This leads to immune evasion and disease progression. Adoptive infusion of healthy donor #NK cells can restore immune surveillance offering a potential strategy for early intervention. It was an honor and a pleasure to collaborate with @CollaSimona on this work! Read here
https://t.co/5zpAPjmmXV
@MDAndersonNews #CCUS #MDS #NK #celltherapy

[Alejo Rodriguez-Fraticelli @AlejoFraticelli]

🔥New Fraticelli lab publication🔥

“Pre-existing stem cell heterogeneity dictates clonal responses to the acquisition of leukemia driver mutations”

Two new figures compared to the pre-print, with more in vivo and sequential mutagenesis data.

https://t.co/2MByy2tcO0

[AML Hub @AML_Hub]

CONGRESS | #EBMT25 @TheEBMT | PRESENTATION
Everett Meyer, @StanfordMed, shares results from the phase III Precision trial (NCT05316701) comparing orca-T with standard-of-care allograft with tacrolimus/methotrexate in patients with AML, ALL, MDS, or MPAL. The trial met its primary endpoint; the rate of survival free of moderate-to-severe chronic GvHD was significantly higher with orca-T vs Tac/MTX (HR: 0.26; p <0.00001).
Follow our live feed for more updates: https://t.co/xkoupl5raq… #AMLsm #leusm #MedicalCongress #ALLsm #MDSsm #GvHD

[Emma M. Groarke @emmamgroarke]

Gene therapy for #telomere biology disorders 🧬! Report of first 2 patients @NEJMEvidence by Kas Myers using vector to increase expression of ZSCAN4 to elongate telomeres. Some TL elongation in HSPCs but low numbers. Will be interested to see more data! https://t.co/DRcO1zgU88

[CU Anschutz Lymphoma Program @CULymphoma]

Dr. @majorajay @CULymphoma (as well as incoming @CUHematology lymphoma faculty Dr. @cduarte8490) contributed to a large study of patients with Hodgkin lymphoma refractory or intolerant to BV and checkpoint inhibitors. #lymsm cc @tvoorheesmd

[Vincent Alcazer @AlcazerVincent]

CAR T or NK cells targeting mismatched HLA-DR molecules in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant
https://t.co/5r3Jt5bnvD

[Hagop Kantarjian,MD @DrHKantarjian]

Expert recommendations on using MRD in #ALL now out in @BloodAdvances. ClonoSEQ (NGS MRD) is superior to other MRD methods and should guide decisions about CAR T-cells or SCT
@MDAndersonNews #Leukemia
https://t.co/eQLDCAbR4H
#leusm